Acute Megakaryoblastic Leukemia: Importance of Bone Marrow Biopsy in Diagnosis.

Abstract:

:Five cases of megakaryoblastic leukemia, presenting as "de novo" acute leukemias are reported. They represented 7.2% of all cases of adult acute non-lymphoblastic leukemias (ANLL) seen in our Hematology Service during the past 30 months. These cases showed features of predominantly blast proliferation with a marked increase of reticulin fibres in the bone marrow. One case had features of acute leukemia with trilineage myelodysplasia and one had a more chronic evolution with splenomegaly initially resembling a myeloproliferative syndrome. In all cases, the definitive diagnosis was made on bone marrow histology as cytology was poor and the blast cells were positive for factor VIII with the immunoperoxidase technique. The importance of bone marrow histology is emphasized.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Lorand-Metze I,Vassallo J,Aoki RY,De Souza CA

doi

10.3109/10428199109107060

subject

Has Abstract

pub_date

1991-01-01 00:00:00

pages

75-9

issue

1

eissn

1042-8194

issn

1029-2403

journal_volume

4

pub_type

杂志文章
  • Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.

    abstract::Chronic myeloid leukemia (CML) results from the Philadelphia chromosome (Ph) translocation and expression of its fusion oncoprotein BCR-ABL1. BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the standard therapy for Ph-positive CML. Achievement of deep molecular responses (typically defined as ≥4-log reduction in BCR-AB...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2016.1190974

    authors: Arora R,Press RD

    更新日期:2017-01-01 00:00:00

  • Systemic mast cell disease with marrow and splenic involvement associated with chronic myelomonocytic leukemia.

    abstract::Systemic mast cell disease (SMCD) has a highly variable clinical expression and course. That SMCD is associated with hematologic disorders has been widely described. We report an unusual case of systemic mast cell disease and concurrent chronic myelomonocytic leukemia in a 60 year old male. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909167403

    authors: Smith JD,Lazarchick J

    更新日期:1999-01-01 00:00:00

  • Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.

    abstract::The occurrence of acute myeloid leukemia (AML) as a secondary tumor has been frequently reported in patients who received various chemotherapy regimens for hematologic malignancies wile the concomitant development of chronic lymphoproliferative diseases (CLD) and AML in previously untreated patients is extremely rare....

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097666

    authors: Montefusco E,Fazi F,Cordone I,Ariola C,Nanni M,Spadea A,Spiriti MA,Fenu S,Mandelli F,Petti MC

    更新日期:2001-02-01 00:00:00

  • A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.

    abstract::The V617F mutation of the JAK2 tyrosine kinase is found in a majority of patients with myeloproliferative disorders. Flow cytometry assays for quantitation of phosphorylated and total protein for JAK2, STAT5, and heat shock proteins (HSPs) were developed to facilitate the study of the JAK/STAT pathway. A cell line hom...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701607576

    authors: Bareng J,Jilani I,Gorre M,Kantarjian H,Giles F,Hannah A,Albitar M

    更新日期:2007-11-01 00:00:00

  • Combination of t(14;18) and a Burkitt's type translocation in B-cell malignancies.

    abstract::The combination of chromosomal translocations associated with bcl-2 rearrangement [t(14;18)] and c-myc rearrangement [t(8;14), t(8;22), or t(2;8)] has infrequently been detected in lymphoproliferative disorders. We have recently identified four cases of a B-cell malignancy exhibiting this dual translocation. In additi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309148200

    authors: Karsan A,Gascoyne RD,Coupland RW,Shepherd JD,Phillips GL,Horsman DE

    更新日期:1993-08-01 00:00:00

  • Acquired C1 esterase inhibitor deficiency in lymphomas: prevalence, symptoms, and response to treatment.

    abstract::We retrospectively studied the prevalence of C1 esterase inhibitor (C1 INH) deficiency in 131 patients with various lymphomas. We determined C1 INH activity, C1 INH antigen, and C4 concentration at diagnosis and after chemotherapy. In follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1131273

    authors: Bekos C,Perkmann T,Krauth M,Raderer M,Lechner K,Jaeger U

    更新日期:2016-09-01 00:00:00

  • Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates.

    abstract::We investigated the possibility of immunotherapy for multiple myeloma (MM) using myeloma-specific cytotoxic T lymphocytes (CTLs) that were stimulated in vitro by dendritic cells (DCs) pulsing with purified and optimized myeloma lysates. CD14(+) cells were cultured in the presence of GM-CSF and IL-4. On day 6, the imma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701583975

    authors: Lee JJ,Choi BH,Kang HK,Park MS,Park JS,Kim SK,Pham TN,Cho D,Nam JH,Kim YJ,Rhee JH,Yang DH,Kim YK,Kim HJ,Chung IJ

    更新日期:2007-10-01 00:00:00

  • CLL Trials in the United Kingdom the Medical Research Council CLL Trials 1, 2 and 3.

    abstract::The MRC has conducted randomised trials in CLL sine 1978: CLL 1 (1978-84), 660 patients; CLL 2 (1984-90), 640 patients; CLL 3 (from June 1990), 90 patients. Centralised morphological diagnosis and membrane marker studies have allowed the exclusion of non-CLL disorders. Some of the treatment questions were repeated in ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109103389

    authors: Catovsky D,Richards S,Fooks J,Hamblin TJ

    更新日期:1991-01-01 00:00:00

  • Risk group definition in children with acute myeloid leukemia by calculating individual risk factors on the basis of a multivariate stepwise Cox regression analysis.

    abstract::To define risk groups in children with acute myeloid leukaemia (AML), we conducted a multivariate stepwise Cox regression analysis of three consecutive multicentre studies in East Germany. The total number of patients was 240, but cytogenetics and remission status on day 15 were routinely investigated only in the most...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097754

    authors: Steinbach D,Hermann J,Littlewood T,Zintl F

    更新日期:2001-11-01 00:00:00

  • New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression.

    abstract::Multiple myeloma is a malignant condition that most commonly occurs in the seventh decade of life. Recent improvements in treatment may result in a more favourable outlook for recently diagnosed patients. Multiple myeloma is an incurable clonal B-cell malignancy, which is initially responsive to conventional chemother...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190802475311

    authors: Gertz MA

    更新日期:2008-12-01 00:00:00

  • Study of specific genetic and epigenetic variables in multiple myeloma.

    abstract::Few studies have examined the association between methylenetetrahydrofolate reductase (MTHFR) SNPs, epigenetic changes, and multiple myeloma (MM). We wished to determine genotype distributions for MTHFR 1298AC SNP in cases of MM and healthy controls and to examine whether there is any correlation between the methylati...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.528095

    authors: Hatzimichael E,Dasoula A,Benetatos L,Syed N,Dranitsaris G,Crook T,Bourantas K

    更新日期:2010-12-01 00:00:00

  • 90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma.

    abstract::Radioimmunotherapy using (90)Y-ibritumomab tiuxetan has predominantly been used in patients with follicular lymphoma, but little is known about its activity in patients with extranodal marginal zone lymphoma of the mucosa associated lymphoid tissue (MALT). A total of six patients progressing/relapsing following conven...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.534519

    authors: Hoffmann M,Troch M,Eidherr H,Traub-Weidinger T,Jonak C,Muellauer L,Raderer M

    更新日期:2011-01-01 00:00:00

  • Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia.

    abstract::All patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) and treated over a 17-year period at a single institution were retrospectively analyzed. From 1990 to 2000, 40 patients were treated with a variety of adult-based ALL regimens. From 2000 to 2007, a pediatric-based protocol, DFCI (Dana Farber...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903388376

    authors: Al-Khabori M,Minden MD,Yee KW,Gupta V,Schimmer AD,Schuh AC,Xu W,Brandwein JM

    更新日期:2010-01-01 00:00:00

  • Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.

    abstract::High-dose melphalan therapy with peripheral blood stem cell (PBSC) transplantation is a standard treatment for younger patients with untreated multiple myeloma that results in high overall and complete response (CR) rates, and improved event-free and overall survival compared with standard chemotherapy alone. Inductio...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190701540991

    authors: Oakervee H,Popat R,Cavenagh JD

    更新日期:2007-10-01 00:00:00

  • Multidrug resistance (Mdr1) gene expression in peripheral blasts from patients with acute leukemia only rarely increases during disease progression after combination chemotherapy.

    abstract::Multidrug resistance gene (mdr1) RNA levels were determined in 55, and P-glycoprotein expression in 37 samples of peripheral leukemic cells from 17 patients with acute myeloblastic leukemia (AML) and 7 patients with acute lymphocytic leukemia (ALL). Between sample collections, patients were treated with various chemot...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509059642

    authors: Gruber A,Areström I,Albertioni F,Björkholm M,Peterson C,Vitols S

    更新日期:1995-08-01 00:00:00

  • Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.

    abstract::Post-transplant lymphoproliferative disorder (PTLD) caused by Epstein-Barr virus (EBV) is a severe complication in high-risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. Central nervous system (CNS) involvement of PTLD is a very rare event in patients with HSCT. As no established standard therapy i...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428194.2012.718342

    authors: Czyzewski K,Styczynski J,Krenska A,Debski R,Zajac-Spychala O,Wachowiak J,Wysocki M

    更新日期:2013-03-01 00:00:00

  • Clinical significance of pre- and 1-year post-transplant serum ferritin among adult transplant recipients.

    abstract::To clarify the significance of post-transplant serum ferritin (SF), we retrospectively assessed pre- and post-transplant SF. Among 256 patients undergoing allogeneic stem cell transplant (SCT) for hematologic malignancies between 2000 and 2011, those who had relapsed within 1 year were excluded, and 110 patients survi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.842981

    authors: Tachibana T,Tanaka M,Numata A,Matsumoto K,Tomita N,Fujimaki K,Taguchi J,Sakai R,Fujita H,Fujisawa S,Maruta A,Ishigatsubo Y,Kanamori H

    更新日期:2014-06-01 00:00:00

  • Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized

    abstract::This post-hoc subanalysis of the LYM-3002 phase 3 study assessed the efficacy and safety of substituting vincristine in rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHOP; n = 42) for bortezomib (VR-CAP; n = 38) in a subgroup of 80 mantle cell lymphoma (MCL) patients aged <60 years who did not receive ste...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/10428194.2017.1365855

    authors: Drach J,Huang H,Samoilova O,Belch A,Farber C,Bosly A,Novak J,Zaucha J,Dascalescu A,Bunworasate U,Masliak Z,Vilchevskaya K,Robak T,Pei L,Rooney B,van de Velde H,Cavalli F

    更新日期:2018-04-01 00:00:00

  • Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective 'Deutsche Studiengruppe MM' (DSMM) and 'European Myeloma Network' (EMN) analysis.

    abstract::Multiple myeloma (MM) often presents with unspecific symptoms and is challenging to diagnose. We performed this DSMM/EMN-analysis via test-(retro-) and validation (prospective) study to determine the time interval from the onset of first symptoms to the diagnosis of MM. The retrospective and prospective analyses were ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1695051

    authors: Graziani G,Herget GW,Ihorst G,Zeissig M,Chaidos A,Auner HW,Duyster J,Wäsch R,Engelhardt M

    更新日期:2020-04-01 00:00:00

  • The role of natural killer cells in immunity against multiple myeloma.

    abstract::Multiple myeloma (MM) is an essentially incurable malignancy associated with profound immune dysregulation. Despite the advent of novel therapies and improvements in survival over the last 10 years, death from progressive disease and infection remains a common outcome. Natural killer (NK) cells are CD56(+)CD3(-) large...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2012.676175

    authors: Godfrey J,Benson DM Jr

    更新日期:2012-09-01 00:00:00

  • Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.

    abstract::Twenty-nine patients with non-Hodgkin's lymphoma received a single subcutaneous injection of 6 mg pegfilgrastim approximately 24 h after the start of CHOP chemotherapy. The safety of pegfilgrastim in this patient population was determined by reports of adverse events. The pharmacokinetics of pegfilgrastim were charact...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.1080/1042819031000063462

    authors: George S,Yunus F,Case D,Yang BB,Hackett J,Shogan JE,Meza LA,Neumann TA,Liang BC

    更新日期:2003-10-01 00:00:00

  • Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia.

    abstract::Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). However, resistance is occasionally observed, mainly due to mutations within the BCR-ABL kinase domain. The T315I substitution confers complete resistance to all TKIs commonly used in clinical practice. To date, the ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.520774

    authors: Chomel JC,Sorel N,Bonnet ML,Bertrand A,Brizard F,Roy L,Guilhot F,Turhan AG

    更新日期:2010-11-01 00:00:00

  • Suppression of cytomegalovirus-specific CD8(+)T cells by everolimus.

    abstract::Abstract Everolimus (RAD-001) has recently been used as an immunosuppressive drug to treat patients after hematopoietic stem cell transplant (HSCT), thereby reducing cyclosporine-related nephrotoxicity. We studied the immunomodulatory effect of everolimus on mitogen-stimulated and particularly cytomegalovirus (CMV)-sp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.822496

    authors: Jin N,Malcherek G,Mani J,Zurleit R,Schmitt A,Chen B,Freund M,Ho AD,Schmitt M

    更新日期:2014-05-01 00:00:00

  • Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen.

    abstract::The genomic profile of mantle cell lymphoma (MCL) has been reported to be significantly different from that of other indolent lymphoproliferative disorders, Topoisomerase IIalpha, glutathione-s-transferasepi (GSTpi) and ABCG2 (BCRP) chemoresistance genes being over-expressed in MCL. In our study, expression levels of ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701402895

    authors: Galimberti S,Nagy B,Benedetti E,Pacini S,Brizzi S,Caracciolo F,Papineschi F,Ciabatti E,Guerrini F,Fazzi R,Canestraro M,Petrini M

    更新日期:2007-08-01 00:00:00

  • Are activation markers (CD25, CD38 and CD103) predictive of sensitivity to purine analogues in patients with T-cell prolymphocytic leukemia and other lymphoproliferative disorders?

    abstract::T-cell prolymphocytic leukemia (T-PLL) is a rare lymphoproliferative disorder with distinctive clinical and laboratory features. It is often resistant to conventional chemotherapy, but complete or partial responses have been documented with the use of purine analogues. We report on two cases of T-PLL with a slightly d...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000040035

    authors: Delgado J,Bustos JG,Jimenez MC,Quevedo E,Hernandez-Navarro F

    更新日期:2002-12-01 00:00:00

  • Plasma cell tumors in HIV-positive patients: report of a case and review of the literature.

    abstract::Plasma cell tumors show an increased incidence in HIV-positive patients. The cases reported in the literature suggest that plasma cell tumors occur in a younger age group than that encountered in the general population. Pathologically, many of these tumors show a plasmablastic morphology. Plasma cell tumors in HIV-pos...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190500054566

    authors: Salarieh A,Rao C,Gottesman SR,Alagha O,Todor R,Axiotis CA

    更新日期:2005-07-01 00:00:00

  • Granulocytic sarcoma: an unusual complication of aleukemic myeloid leukemia causing spinal cord compression. A case report and literature review.

    abstract::Granulocytic sarcoma (chloroma) is a rare solid tumor resulting from the proliferation of myelogenous leukemia cells. Chloromas usually present as soft tissue or bony masses of the head and neck in patients with acute myelogenous leukemia (AML) of the French-American-British M2 subtype. Occasionally chloromas may occu...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819031000104051

    authors: Landis DM,Aboulafia DM

    更新日期:2003-10-01 00:00:00

  • Daratumumab for the treatment of AL amyloidosis.

    abstract::Autologous stem cell transplantation (ASCT) has been used as treatment for immunoglobulin light-chain (AL) amyloidosis for over two decades with improving outcomes; however, the majority of patients are not candidates for this therapy at diagnosis. Novel agents such as immunomodulatory drugs, proteasome inhibitors, an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2018.1485914

    authors: Sidiqi MH,Gertz MA

    更新日期:2019-02-01 00:00:00

  • Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study.

    abstract::Eighteen patients (pts) with myelodysplastic syndrome (MDS) were treated with thymopentin (TP) (50 mg subcutaneously for 5 days) and recombinant interferon alpha 2a (rIFN alpha 2a) (3 MU/m2 subcutaneously on the sixth day); the courses were delivered every week. Moreover those pts with > or = 10% blasts in the bone ma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509049773

    authors: Venditti A,Scimò MT,del Poeta G,Buccisano F,Stasi R,Mastino A,Grelli S,Favalli C,Garaci E,Papa G

    更新日期:1995-01-01 00:00:00

  • Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study.

    abstract::Richter's transformation (RT) refers to the development of an aggressive lymphoma in patients with chronic lymphocytic leukemia (CLL). Approximately, 2-10% of patients with CLL develop RT, most often as diffuse large B-cell lymphoma. To assess the incidence of RT, we examined risk factors for RT and death among patien...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1719092

    authors: Ben-Dali Y,Hleuhel MH,da Cunha-Bang C,Brieghel C,Poulsen CB,Clasen-Linde E,Bentzen HHN,Frederiksen H,Christiansen I,Nielsen LH,Enggaard L,Helleberg M,Clausen M,Frederiksen M,Pedersen RS,Niemann CU,Andersen MA

    更新日期:2020-06-01 00:00:00